This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, T. F. Articles by Frankel, A. E. Search for Related Content PubMed PubMed Citation Articles by Liu, T. F. Articles by Frankel, A. E.

Interstitial Diphtheria Toxin-Epidermal Growth Factor Fusion Protein Therapy Produces Regressions of Subcutaneous Human Glioblastoma Multiforme Tumors in Athymic Nude Mice

¹ Department of Medicine, Pathology, and Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina ² Department of Pharmaceutical Sciences, Medical University Of South Carolina, Charleston, South Carolina, USA

Requests for reprints: Arthur E. Frankel, Wake Forest University School of Medicine, Hanes 5045, Medical Center Boulevard, Winston-Salem, NC 27157. Phone: 336-716-3313; Fax: 336-716-9113; E-mail: afrankel{at}wfubmc.edu.

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Purpose: The novel fusion protein, DAB₃₈₉EGF, composed of the catalytic and translocation domains of diphtheria toxin (DAB₃₈₉) fused with a His-Ala linker to human epidermal growth factor (EGF) was tested for antiglioma efficacy in an in vivo model of human glioma.

Experimental Design: Female athymic nude mice (ages 4-6 weeks) were inoculated s.c. with 10 million U87MG human glioma cells in the right flank. When tumor volumes reached 100 mm³ (6-8 days), i.t. injections of saline, DAB₃₈₉IL2, or DAB₃₈₉EGF 1, 3, 5 or 10 µg in 50 µL were given every other day for three to six doses. Animals were monitored twice daily and tumor measurements were made by calipers.

Results: The maximal tolerated dose (MTD) of DAB₃₈₉EGF was 3 µg every other day. Above the MTD, animals experienced loss of activity, reduced oral intake, and dehydration. Blood chemistries confirmed elevated blood urea nitrogen, creatinine, aspartate transaminase, and alanine transaminase. Histopathology revealed renal tubular necrosis. At the MTD, tumor regression was seen in all animals. Relapses occurred in 4 of 16 (25%) of animals after 1 month. These tumors contained EGF receptor, were sensitive in vitro to DAB₃₈₉EGF, and responded to a second course of i.t. DAB₃₈₉EGF.

Conclusions: DAB₃₈₉EGF fusion protein shows in vivo antiglioma efficacy in a s.c. tumor model and warrants further preclinical testing in an i.c. tumor model for eventual treatment of patients with recurrent or refractory EGF receptor–positive glioblastoma multiforme.

Key Words: glioblastoma multiforme • diphtheria toxin • epidermal growth factor receptor • fusion protein

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
There are 18,000 new cases of primary brain tumors per year in the United States (1). Most patients progress and die from their disease. For the most common variety, glioblastoma multiforme, the median survival is 1 year for newly diagnosed patients and 6 months for patients with recurrent disease (2). Fewer than 20% of glioblastoma multiforme patients are alive at2 years. These tumors are radiotherapy and chemotherapy resistant (3). Novel agents with different mechanisms of action are needed for brain tumor patients.

One novel class of brain tumor therapeutics is fusion proteins consisting of brain tumor–selective ligands conjugated to peptide toxins. The ligands direct the agent to the glioma cell surface. The peptide toxins then internalize into the cell, translocates to the cytosol, and catalytically inactivates protein synthesis, leading to cell death. A series of brain tumor fusion proteins have been prepared and had antiglioma activity in tissue culture, in animal models, and in patients (4–12). The fusion proteins are delivered to the tumor cells by convection enhanced delivery (CED). Catheters are introduced into the tumor bed or normal brain surrounding the tumor resection cavity (12); continuous fluid pressure over several days is added to create a bulk flow, which supplements diffusion. CED achieves high protein concentrations in a large volume of the tumor and surrounding brain tissue. The protein concentrations are orders of magnitude higher than would be achieved by systemic administration or bolus i.t. injections (13). Clinical remissions lasting years have been observed in many patients (4, 6, 12). Because of toxicities to normal brain tissue and heterogeneity of receptor expression among brain tumors, there is a need for additional brain tumor fusion proteins.

We chose a diphtheria fusion protein composed of the catalytic and translocation domains of diphtheria toxin (DAB₃₈₉) fused via a His-Ala linker to epidermal growth factor (EGF). DAB₃₈₉EGF was expressed in Escherichia coli and purified from inclusion bodies as described previously (14). The fusion protein was 48,522-Da, reacted with antibodies to diphtheria toxin and EGF on immunoblots, and was selectively toxic to EGF receptor (EGFR)–overexpressing tumor cell lines xd (15). We showed potent DAB₃₈₉EGF toxicity to a battery of glioma cell lines (16). Efficacy was proportional to EGFR density. We also examined receptors densities for different fusion proteins among a large set of human brain tumors. EGFR was more frequently expressed and at a higher level than the other examined receptors (17). We wanted to extend this work to an invivo brain tumor system. In this report, we describe the antiglioma efficacy of DAB₃₈₉EGF in a human glioma-athymic nude mouse xenograft model and better characterize the maximal tolerated dose (MTD) and dose-limiting toxicity of i.t. therapy. Further, we explore models of DAB₃₈₉EGF-mediated in vivo brain tumor cell death. The results establish that the excellent anti–brain tumor activity of DAB₃₈₉EGF extended to an interstitial therapy animal model and provide a rationale for CED DAB₃₈₉EGF therapy of patients with recurrent EGFR positive gliomas.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cells. The human glioma cell line U87MG was purchased from the American Type Culture Collection (Rockville, MD) and were grown in Eagle's medium containing sodium pyruvate, 10% fetal bovine serum, nonessential amino acids, L-glutamine, penicillin/streptomycin, and 1.5 g/L sodium bicarbonate. Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO₂ in air.

Animals. Female athymic nude mice (ages 4-6 weeks) were obtained from Charles River Laboratories (Wilmington, MA) and BALB/c mice (female, ages 8 weeks) were obtained from Harlan (Indianapolis, IN) and maintained in a ventilated rack system. Irradiated food and autoclaved water were provided adlibitum. The mice were allowed to adjust to their environment for 1 week. The athymic nude mice were then injected s.c. in the right flank with 10 million U87MG cells diluted in 0.1 mL PBS (BioWhittaker, Walkersville, MD). After completion of all injections, cells from residual syringes were >90% viable by trypan blue exclusion. Animals were observed twice daily, and tumor size was measured every other day with calipers. The tumor volume was calculated based on the formula: (L x W²) / 2, where L is length and W is width. Groups of five BALB/c mice received two DAB₃₈₉EGF or saline s.c. injections of 10 µg every other day and were euthanized and necropsied on day 5. Blood samples were obtained at the time of euthanasia by cardiac puncture and assayed for serum chemistries.

Drugs. DAB₃₈₉EGF was synthesized and partially purified as described previously (15). Vials contained 500 µg sterile-filtered, lyophilized DAB₃₈₉EGF in PBS (pH 7.2) containing 1% mannitol and 50 µmol/L EDTA (Ligand Pharmaceuticals, San Diego, CA). Vials were stored at –80°C. Fusion protein was prepared for experiments by adding 2 mL sterile water and gently stirring. Dissolved protein was stored at 4°C. DAB₃₈₉IL2 (denileukin diftitox, Ontak) was also obtained from Ligand Pharmaceuticals, diluted in PBS to 0.15 mg/mL, and stored at 4°C.

Necropsies. Mice that presented severely dehydrated, hypothermic, and dyspneic were considered moribund and were euthanized by standard CO₂ asphyxiation, consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. Blood samples were collected by cardiac puncture and assayed for serum chemistries. All other mice were euthanized before mass size was 1,500 to 3,000 mm³. All mice were killed at day 60 post-tumor cell inoculation. Samples from major organs were removed, fixed in 10% buffered formaldehyde, dehydrated, and embedded in paraffin. Sections were stained with H&E and examined under the microscope.

Efficacy Studies. Groups of 5 to 16 animals received i.t. injections of 1, 3, 5, or 10 µg DAB₃₈₉EGF, 10 µg DAB₃₈₉IL2, or saline in 50 µL volume beginning when tumor volume reached 100 mm³ (6-8 days). Treatments were repeated every other day for 2 weeks. The mice were examined twice daily for overall activity, and bidirectional tumor diameters were measured with calipers every other day for 8 weeks. Moribund mice were killed. Three 3 µg DAB₃₈₉EGF-treated animals developed recurrent tumors after 1 month and received a second identical course. On day 60, the skin tumor sites of DAB₃₈₉EGF-treated mice were examined, fixed in 10% buffered formaldehyde, dehydrated, embedded in paraffin, sectioned, and stained with H&E.

Tumor Studies. Tumor samples were collected and divided into three portions. One portion was fixed in 10% buffered formaldehyde, dehydrated, embedded in paraffin, sectioned, and stained with H&E. Another portion was frozen and 6-µm cryostat sections were made and reacted with anti-EGFR or control mouse immunoglobulin and washed, and bound antibody was detected with rhodamine-conjugated goat anti-mouse immunoglobulin as described previously (17). Staining intensities of control and relapsed tumor sections with similar cell densities were examined on a Zeiss Axioplan epifluorescence microscope with an Axiocam CCD camera and relative rhodamine fluorescence intensity was analyzed by morphometric quantitation using Adobe Photoshop as described previously (17). A third portion of the tumor was minced, 0.25% trypsin digested, and dispersed in Eagle's medium supplemented as described above. Cell cytotoxicity assays were then done with [³H]leucine and/or [³H]thymidine as described previously (16), and results were expressed as IC₅₀s (concentration of DAB₃₈₉EGF yielding 50% control thymidine or leucine incorporation).

Pharmacokinetic Studies. Tumor-bearing and control nude mice were injected i.t. and i.v. with 3 µg DAB₃₈₉EGF and blood samples were obtained pretreatment and at 5, 30, 60, and 90 minutes post-treatment. Sera were isolated and saved at –80°C. Dilutions of mouse serum in medium were tested along with known dilutions of DAB₃₈₉EGF in pretreatment mouse sera in medium on U373MG cells by the previously described [³H]thymidine incorporation inhibition assay (16) and serum concentrations were calculated based on the IC₅₀ ratios.

Immunogenicity Studies. BALB/c mice were injected s.c. with 150 µg/kg DAB₃₈₉EGF every other day for six doses. At day 25, mice were euthanized and blood samples were collected via cardiac puncture. Blood samples from nontreated mice were used as a negative control. Sera were stored at –80°C until assayed. Anti–diphtheria toxin antibodies were assayed as described previously with the substitution of DAB₃₈₉EGF for DT₃₈₈GMCSF (18).

Statistical Analysis. Survival was analyzed by the Kaplan-Meier method. For comparison of tumor volumes, weights, activated caspases by immunoblot density, EGFR densities, and IC₅₀s, a Mann-Whitney or Kruskal-Wallis test was used. Significance of differences was assumed at P 0.05.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
MTD of DAB₃₈₉EGF. The MTD of DAB₃₈₉EGF given i.t. was 3 µg every other day for 6 to 12 doses. No deaths were observed among 16 animals (Fig. 1). In contrast, animals receiving 5 or 10 µg doses (n = 8) had a mortality of 25% and 87%, respectively.

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Fig. 1 Female athymic nude mice (ages 4-6 weeks) were inoculated with 10 million U87MG tumor cells on day 0. When tumors had reached 100 mm3 in volume (day 7), i.t. injections of DAB389EGF or DAB389IL2 were given every other day. Cohorts of eight animals were treated. One group received DAB389IL2 at 10 µg per dose on days 6-16 for a total of six doses (). A second group received DAB389EGF at 3 µg per dose on days 6-16 (a total of 6 doses) and for two mice repeat injections on days 22-32 (a total of 12 doses; ). A third group received DAB389EGF at 5 µg per dose on days 6-16 and 28-34 (a total of 9 doses;). A final group received DAB389EGF at 10 µg per dose on days 6-10 or 14 for a total of 3 to 5 doses ().

View larger version (167K): [in this window] [in a new window] [Download PPT slide]   Fig. 2 Histopathology of liver and kidney of control mice treated with PBS i.t. every other day for 5 doses (A and B) and moribund mice treated with DAB389EGF 10 µg i.t. every other day for 3 doses (C and D). A and C, liver histology; B and D, kidney histology. Livers of DAB389EGF-treated mice showed single apoptotic cells (). Kidneys of DAB389EGF-treated mice showed many necrotic tubules (). PBS-treated mice livers and kidneys show no injury. Magnification, x400.

View larger version (16K): [in this window] [in a new window] [Download PPT slide]   Fig. 3 Three athymic nude mice bearing U87MG tumors were given i.t. injections of DAB389EGF 5 µg per mouse every other day for 3 doses (). On day 21, animals had lost significant weight and had decreased activity. Hydration was initiated with 0.5 mL saline to all three mice (). For two of the mice, 0.5 mL saline was continued on days 24-27 (). , mouse 1; , mouse 2; , mouse 3(– –).

U87MG Tumor Growth in Athymic Nude Mice. Athymic nude mice (n = 26) inoculated s.c. with U87MG glioma cells showed rapid tumor growth. Mean ± SE tumor volume reached 112 ± 15 mm³ by day 7. The tumor then doubled in volume (209 ± 27 mm³) by day 12 and doubled again (620 ± 72 mm³) by day 18. The mean tumor volume continued to double with a doubling time of 4 days until animals were sacrificed on day 29 (mean tumor volume = 3,115 ± 756 mm³). Based on these results, we could detect a 25% or 50% tumor growth inhibition with 15 or 5 animals per group, respectively, with a two-sided type I error of 5% and a power of 0.90. Pathology of the tumor confirmed the malignant histology.

Antiglioma In vivo Efficacy of Diphtheria Fusion Proteins. We initially explored the antiglioma activity in vivo of different doses of DAB₃₈₉EGF i.t. versus saline control in cohorts of five animals (Fig. 4A). At day 30, the control tumors were 3,220 ± 760 mm³; the 1 µg dose tumors were 543 ± 261 mm³ (compared with control; P = 0.01); the 5 µg dose tumors were 176 ± 132 mm³ (compared with control; P = 0.005); and the two 10 µg dose tumors were 0 mm³. Because of the excessive toxicities of the 5 and 10 µg doses, we selected 3 µg for further study. Cohorts of 16 animals were treated with 3 µg DAB₃₈₉EGF or 10 µg DAB₃₈₉IL2 i.t. every other day for six doses (Fig. 4B). The DAB₃₈₉EGF-treated animals showed tumor growth inhibition. On day 29, the PBS control tumors were 3,115 ± 756 mm³, the DAB₃₈₉IL2-treated tumors were 1,682 ± 358 mm³ (P = 0.644 versus control), and the DAB₃₈₉EGF-treated tumor were 1 ± 1 mm³ (P = 0.0001 versus control). By day 60, 12 of 16 (75%) DAB₃₈₉EGF-treated mice remained in remission both grossly and by histopathology. Three animals had tumor recurrence and received a second course of DAB₃₈₉EGF. One of these animals became disease free at day 60 both grossly and by histology. Two of the retreated animals again had tumor regrowth by day 60 of 20 and 85 mm³. One animal had no visible tumor regrowth and was not treated with a second course but showed five tumor cells in the skin by microscopic histopathology on day 60.

View larger version (18K): [in this window] [in a new window] [Download PPT slide]   Fig. 4 U87MG glioma tumor size in athymic nude mice. A, i.t. injections of PBS (), 1 µg DAB389EGF (), 5 µg DAB389EGF (), or 10 µg DAB389EGF (); filled arrows, treatments at all dose levels; hollow arrows, treatments only for 1 and 5 µg DAB389EGF doses. B, i.t. injections of 3 µg DAB389EGF () or 10 µg DAB389IL2 (). Filled arrows, treatments on days 6-16; hollow arrows, treatment of two relapsing tumors on days 22-30. C, i.t. injections for relapsed tumors of individual mice (1, 2, 3, 4, 5, 6, 7, and 8, ); bars, 5 µg DAB389EGF treatments on days 8-16, 28-34, and 42-48.

DAB₃₈₉EGF Pharmacokinetics and Immune Response. The serum levels after i.t. administration of DAB₃₈₉EGF were immeasurable at all time points (<5 ng/mL). In contrast, after i.v. administration, the half-life was 30 minutes with peak level of 14 ± 7 ng/mL from a 3 µg dose. Antibodies to diphtheria toxin were absent in four of five control mice (<1 ng/mL) andat1 µg/mL in the fifth control mouse (mean = 0.2 ± 0.4µg/mL). In contrast, on day 25 after the 2-week treatment course, all five mice had elevated antibody levels (mean = 1028 ± 532 µg/mL). The difference from control mice was significant (Student t test P = 0.006 ).

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The fusion protein DAB₃₈₉EGF is tolerated by rodents at doses that have significant antitumor activity when given i.t. The MTD of 3 µg per mouse corresponds to 150 µg/kg and is 4-fold higher than the MTD with i.v. administration (15). The short half-life of DAB₃₈₉EGF in the blood combined with a slow escape of the drug from the tumor into the vasculature produced very low blood concentrations. This may contribute to the reduced toxicity. Because other species, including humans, have similar distribution of EGFR, the results from this study should be applicable to the clinical setting. However, studies of i.t. infusions into the brain need to be done with orthotopic i.c. rodent tumor models to confirm safety, efficacy, toxicology, pharmacokinetics, and immunology.

A complicating factor with i.t. CED is poor distribution of drug outside the tumor mass. The tumor may create an "antigenic sink" for the drug and responses may be improved by CED to postsurgical resection adjacent brain (12). Such pharmacologic considerations are poorly modeled in animals and will be repeated during clinical trials.

The target normal organ of i.t. DAB₃₈₉EGF appeared to be the kidney. These results match previous observations of DAB₃₈₉EGF in rats, monkeys, and patients. The presence of EGFR on renal tubule cells suggests the toxicity is ligand directed. We observed that hydration was able to reverse toxicity in a fraction of moribund animals. Such hydration may be useful in patients displaying DAB₃₈₉EGF renal injury.

Repeat administration of the fusion protein produces an immune response after systemic administration to immunocompetent animals and patients. We observed anti–diphtheria toxin antibodies 4 weeks after initiation of DAB₃₈₉EGF s.c. infusions in immunocompetent BALB/c mice. Thus, additional studies are needed in immunocompetent rodent glioma models to confirm efficacy of repeated courses.

The dramatic antiglioma effects observed in this study are equal to or better than those reported with other fusion proteins (8–12, 19–23). Because several of these proteins have yielded complete remissions in refractory glioma patients (4–8, 12), the results suggest that DAB₃₈₉EGF will likely be useful when given by CED to such patients. This fusion protein is distinct from other clinically tested brain tumor fusion proteins both with regard to the toxin and ligand. The EGFR level in the tested U87MG human glioma cells was 65,000 per cell (16). EGFR is overexpressed on 84% of human high-grade gliomas (17). EGFR is truncated in some gliomas leading to constitutive activation (EGFRvIII), but most of the glioma cells in these patients also overexpress wild-type EGFR (24). Availability of new potent fusion proteins may overcome immune responses to these agents (25) and fusion protein–specific resistance mechanisms (26). Further, combination therapies with different fusion proteins may yield synergistic efficacy (27, 28).

Re-treatment in our study improved the quality and duration of remissions. Because of the large size of the molecule (45,000 Da), the drug may have limited penetration of the s.c. tumor mass; consequently, deposits of tumor may not receive significant drug and may regrow. Relapsing tumor retains EGFR and DAB₃₈₉EGF sensitivity; thus, it is not surprising the tumor responds to re-treatment. Because this phenomenon may occur after CED, a re-treatment strategy may be useful clinically to consolidate response. However, as noted above, DAB₃₈₉EGF is immunogenic, and methods must be developed to reduce the immunogenicity for optimal efficacy. In summary, this study provides preclinical rationale for the further development of DAB₃₈₉EGF for interstitial therapy of refractory gliomas.

	FOOTNOTES

 
Grant support: NIH grants R01CA76178 (A.E. Frankel), R01CA90263 (A.E. Frankel), and T32RR007009 (K.A. Cohen).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/16/04; revised 9/27/04; accepted 10/11/04.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Jernal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29.[Abstract/Free Full Text]
2. Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systemic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011–8.[CrossRef][Medline]
3. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350–4.[Abstract/Free Full Text]
4. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362–8.[CrossRef][Medline]
5. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92:168–75.[CrossRef][Medline]
6. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105–11.
7. Sampson JH, Akabani G, Archer GE, et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)- and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65:27–35.[CrossRef][Medline]
8. Weber FW, Floeth F, Asher A, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003;88:93–103.
9. Todhunter DA, Hall WA, Rustamzadeh E, et al. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004;17:157–64.[Abstract/Free Full Text]
10. Rustamzadeh E, Li C, Doumbia S, et al. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol 2003;65:63–75.[Medline]
11. Li C, Hall WA, Jin N, et al. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 2002;15:419–27.[Abstract/Free Full Text]
12. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2004;65:37–48.
13. Nguyen TT, Pannu YS, Sung C, et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003;98:584–90.[Medline]
14. Shaw JP, Akiyoshi DE, Arrigo DA, et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 1991;266:21118–24.[Abstract/Free Full Text]
15. Cohen KA, Bissonnette R, Puri RK, et al. Novel fusion protein therapy of refractory brain tumors. Curr Pharm Biotechnol 2003;4:39–49.[CrossRef][Medline]
16. Liu TF, Cohen KA, Ramage JG, et al. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 2003;63:1834–7.[Abstract/Free Full Text]
17. Liu TF, Tatter SB, Willingham MC, et al. Growth factor receptor expression varies among high grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2003;2:783–7.[Abstract/Free Full Text]
18. Hall PD, Kreitman RJ, Willingham MC, et al. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol Appl Pharmacol 1998;150:91–7.[CrossRef][Medline]
19. Hagihara N, Walbridge S, Olson AW, et al. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res 2000;60:230–4.[Abstract/Free Full Text]
20. Kihara A, Pastan I. Small chimeric toxins containing only transforming growth factor and domain III of Pseudomonas exotoxin with good antitumor activity in mice. Cancer Res 1994;54:5154–9.[Abstract/Free Full Text]
21. Engebraaten O, Hjortland GO, Juell S, et al. Intratumor immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 2002;97:846–52.[CrossRef][Medline]
22. Kawkami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol 2003;65:15–25.[CrossRef][Medline]
23. Debinski W, Gibo DM, Hulet SW, et al. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985–90.[Abstract/Free Full Text]
24. Biernat W, Huang H, Yokoo H, et al. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 2004;14:131–6.[Medline]
25. Frankel AE. Reducing the immune response to immunotoxin. Clin Cancer Res 2004;10:13–5.[Free Full Text]
26. de Jong MC, Scheffer GL, Broxterman HJ, et al. Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin except when over-expressing the multi-drug resistance protein MRP1. Clin Cancer Res 2003;9:5009–17.[Abstract/Free Full Text]
27. Liu TF, Cohen KA, Willingham MC, et al. Combination fusion protein therapy of refractory brain tumors: demonstration of efficacy in cell culture. J Neurooncol 2003;65:77–85.[Medline]
28. Liu TF, Willingham MC, Tatter SB, et al. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 2003;14:1107–14.[CrossRef][Medline]

This article has been cited by other articles:

				B. J. Stish, H. Chen, Y. Shu, A. Panoskaltsis-Mortari, and D. A. Vallera A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6486 - 6493. [Abstract] [Full Text] [PDF]

				D. A. Reardon and P. Y. Wen Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist, February 1, 2006; 11(2): 152 - 164. [Abstract] [Full Text] [PDF]

				A. Eramo, R. Pallini, F. Lotti, G. Sette, M. Patti, M. Bartucci, L. Ricci-Vitiani, M. Signore, G. Stassi, L. M. Larocca, et al. Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Destruction Cancer Res., December 15, 2005; 65(24): 11469 - 11477. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, T. F. Articles by Frankel, A. E. Search for Related Content PubMed PubMed Citation Articles by Liu, T. F. Articles by Frankel, A. E.